Bcr-Abl

Inhibitory Selectivity

Show entries

Search:

Catalog No.	Inhibitor Name	Bcr-Abl	Abl	Other
A10080	Ponatinib	****	****	PDGFRα,VEGFR2,FGFR1
A10095	AT9283		***	JAK3,JAK2,Aurora B
A10108	Saracatinib		**	c-Src,LCK,EGFR (L861Q)
A10119	Bafetinib	***	***	Lyn
A10290	Dasatinib	****	****	Src,c-Kit (D816V),c-Kit (wt)
A10468	Imatinib Mesylate		*	c-Kit,PDGFR
A10508	KW-2449	**	***	FLT3 (D835Y),FLT3,FGFR1
A10644	Nilotinib	**
A10661	NVP-BHG712		*	EphB4,C-Raf,c-Src
A10715	Danusertib	**	**	Aurora A,TrkA,RET

Showing 1 to 10 of 21 entries

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Quick View
AP24534 (Ponatinib)

Catalog No. A10080
Quick View

添加到收藏
BCR-ABL 抑制剂

AP24534 (Ponatinib)是有效的多激酶和pan-BCR-ABL抑制剂。了解更多

Product Citations (6)

Bulk Inquiry Free Sample
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Yamamoto Y, .et al. Development of a sandwich enzyme-linked immunosorbent assay for the quantification of ponatinib in serum, Anal Biochem, 2019, Feb 13. pii: S0003-2697(18)31083-2 PMID: 30771339
- N Naganna, .et al. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice, EBioMedicine, 2019, Jan 24. pii: S2352-3964(19)30012-X PMID: 30686755
- Takuya Hirao, .et al. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells, Cancer Sci, 2018, Jan; 109(1): 121-131 PMID: 29121435
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358